This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.
Eiger (EIGR) Up on Positive Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval
by Zacks Equity Research
Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
by Zacks Equity Research
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.71, moving +0.44% from the previous trading session.
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
by Zacks Equity Research
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.
Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.04, moving +0.51% from the previous trading session.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - October 07, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers' Opdivo & Yervoy Win FDA Nod for Mesothelioma
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.
Why the Earnings Surprise Streak Could Continue for Merck (MRK)
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes
by Zacks Equity Research
Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.
The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck & Co., Chipotle Mexican Grill and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck & Co., Chipotle Mexican Grill and IDEXX Laboratories
J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis
by Zacks Equity Research
FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.
Top Analyst Reports for Alibaba, UnitedHealth & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth Group (UNH) and Merck (MRK).